Abstract
Clinical questionWhat are the benefits and harms of sodium-glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists when added to usual care (lifestyle interventions and/or other diabetes...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have